

Resource Summary Report

Generated by [RRID](#) on Aug 28, 2026

SUP-M2

RRID:CVCL_2209

Type: Cell Line

Proper Citation

RRID:CVCL_2209

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2209

Proper Citation: RRID:CVCL_2209

Description: Cell line SUP-M2 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Anaplastic large cell lymphoma, ALK-positive

Defining Citation: [PMID:2525056](#), [PMID:7824924](#), [PMID:9121481](#), [PMID:15356658](#), [PMID:22460905](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:30285677](#), [PMID:30629668](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31160637](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: LL-100 blood cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: SUP-M2

Synonyms: Sup-M2, SUPM2

Cross References: BTO:BTO_0004775, CLO:CLO_0037065, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-MTAB-7721, ArrayExpress:E-MTAB-7722, BioGRID_ORCS_Cell_line:458, BioSample:SAMN03473512, BioSample:SAMN10988021, cancercellines:CVCL_2209, Cell_Model_Passport:SIDM00421, Cosmic:1086004, Cosmic:1152615, Cosmic:1995648, Cosmic-CLP:1331040, DepMap:ACH-000226, DSMZ:ACC-509, DSMZCellDive:ACC-509, EGA:EGAS00001000978, GDSC:1331040, GEO:GSM887660, GEO:GSM888752,

GEO:GSM1670493, IARC_TP53:30176, LiGeA:CCLE_582, LINCS_LDP:LCL-1919, PharmacDB:SUPM2_1521_2019, PRIDE:PXD030304, Progenetix:CVCL_2209, Wikidata:Q54970876

ID: CVCL_2209

Record Creation Time: 20220427T221613+0000

Record Last Update: 20260815T235921+0000

Ratings and Alerts

No rating or validation information has been found for SUP-M2.

No alerts have been found for SUP-M2.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Ianevski A, et al. (2026) Multiomics Profiling of T-cell Leukemia and Lymphoma Enables Targeted Therapeutic Discovery. Cancer research, 86(2), 295.

Fiore D, et al. (2025) A patient-derived T cell lymphoma biorepository uncovers pathogenetic mechanisms and host-related therapeutic vulnerabilities. Cell reports. Medicine, 6(4), 102029.

Ward GA, et al. (2024) Epigenetic Priming by Hypomethylation Enhances the Immunogenic Potential of Tolinapant in T-cell Lymphoma. Cancer research communications, 4(6), 1441.

Pearson JD, et al. (2021) Binary pan-cancer classes with distinct vulnerabilities defined by pro- or anti-cancer YAP/TEAD activity. Cancer cell, 39(8), 1115.

Bai L, et al. (2019) A Potent and Selective Small-Molecule Degradar of STAT3 Achieves Complete Tumor Regression In Vivo. Cancer cell, 36(5), 498.